Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetesSEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor ...

Sana Biotechnology, Inc. (NASDAQ:SANA) operates within the biotechnology sector, focusing on innovative therapies aimed at ...

Detailed price information for Sana Biotechnology Inc (SANA-Q) from The Globe and Mail including charting and trades.

Sana Biotechnology Inc. company facts, information and financial ratios from MarketWatch. Sana Biotechnology Inc. company facts, information and financial ratios from MarketWatch. Skip to main content ...

The market has climbed 1.3% over the last week and is up 13% over the past year, with earnings forecasted to grow by 14% annually. For those looking to invest in smaller or newer companies, penny ...

The CRISPR market is witnessing rapid growth due to its potential to transform gene therapy, diagnostics, and agriculture. With widespread research and commercial interest, the market is poised to ...

The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients ...

Damascus, SANA-Ministry of Higher Education and Scientific Research has announced the availability of scholarships offered by ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall ...